xCures is an AI-assisted healthcare data platform that extracts and structures clinical information from medical records. It uses AI to turn unstructured records into decision-ready insights for healthcare workflows and precision oncology.
Access to pre-IPO shares is available to accredited investors through UpMarket.
xCures shares are not on public exchanges. UpMarket provides accredited investors access through secondary market transactions.
Confirm eligibility under SEC Rule 501 of Regulation D. Income or net worth threshold applies.
Complete KYC/AML onboarding. Typically 1–2 business days. Licensed rep assigned on signup.
Full offering memoranda and risk disclosures provided before any commitment is required.
Review and sign subscription agreement. All documents handled digitally through the platform.
Wire transfer or ACH. $50K minimum. Funds held in custodial account until close.
Pre-IPO investments are illiquid, speculative, and involve risk of total loss of capital.
| Date | Round | PPS (split-adj.) | Valuation |
|---|---|---|---|
| Convertible Round |
xCures announced a $12.69 million Series A led by Boehringer Ingelheim Venture Fund, with participation from Vanedge Capital, Harmonix Fund and Metaplanet. The company said the capital would accelerate adoption and development of its AI-powered precision oncology decision platform.
xCures says its platform extracts, structures and displays clinical information from records gathered across QHINs, HIN/HIE networks, partner systems, uploads and fax or legacy sources. Preqin describes the company as focusing on transforming unstructured health data into actionable datasets for healthcare professionals.
xCures positions its product for precision oncology decision making, a segment it highlighted in its 2021 Series A announcement. Preqin notes the company was founded in 2018, is based in San Francisco, and had raised $12.69 million across multiple rounds by June 2021.
Interested in xCures stock? Fill out the form above or sign up directly. Subject to availability. Accredited investors only.
Request access →UpMarket curates and conducts independent diligence on every investment opportunity before it reaches the platform.
We review every offering's strategy, risk management, liquidity, fees, valuation methodology, tax matters, and all third-party providers — legal counsel, auditor, administrator, and custodian.
We offer investments exclusively from disciplined managers that pursue unique strategies across an array of asset classes.
Our goal is to empower you to build a portfolio that best meets your individual investment objectives.
No. As of March 2026, xCures is a private company and does not trade on any public stock exchange. Accredited investors can access xCures shares through UpMarket, a FINRA-registered broker-dealer that specializes in pre-IPO investments.
xCures does not have a public stock price because it is privately held. The most recent known share price comes from its last funding round. Pre-IPO share prices on the secondary market may differ from the last round price depending on supply, demand, and market conditions.
Yes. Accredited investors can indicate interest in xCures shares through UpMarket by filling out the form on this page or creating an account at upmarket.co. All pre-IPO offerings are subject to availability and require a $50,000 minimum investment. UpMarket is a FINRA-registered broker-dealer and has brokered alternative investments since 2019.
Pre-IPO investments carry significant risks. xCures shares are illiquid, meaning there is no public market to sell them quickly. There is no guaranteed exit timeline or return. The investment is speculative in nature, and investors should be prepared for the possibility of total loss. Valuations of private companies can fluctuate substantially between funding rounds. Investors should consult their financial advisor and review all offering documents before investing.
In a pre-IPO transaction, accredited investors purchase shares from existing shareholders (such as employees, early investors, or other holders) through secondary market platforms. The company itself does not issue new shares in these transactions. UpMarket facilitates these trades as a FINRA-registered broker-dealer, handling compliance, documentation, and settlement on behalf of both parties.
There are two primary exit paths for pre-IPO holdings: selling your shares on the secondary market to another buyer, or holding until the company completes an IPO or is acquired. Both paths are subject to transfer restrictions, company approval (right of first refusal), and market conditions. The timing of any exit is unpredictable, and investors should plan for a multi-year holding period.
The minimum investment for most pre-IPO offerings on UpMarket is $50,000. This amount may vary depending on the specific offering and share availability. There are no fees to create an UpMarket account or browse available investments. Investors only pay transaction-related fees when they complete an investment.
UpMarket's valuation estimate of is derived from a proprietary model that incorporates multiple data sources: funding round data (Caplight), revenue estimates (Sacra), secondary market pricing, and public company comparables. The model applies a private company discount to the public comp multiple to account for illiquidity and information asymmetry. This estimate is not investment advice and may differ substantially from the price at which shares actually trade.
xCures extracts and structures clinical data from medical records with an AI-assisted platform and reported $11.3M in 2026 revenue, after raising a $12.69M Series A to scale its oncology platform — accredited investors can access xCures stock through UpMarket.